<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656795</url>
  </required_header>
  <id_info>
    <org_study_id>MT-7117-Z-101</org_study_id>
    <secondary_id>2020-003333-38</secondary_id>
    <nct_id>NCT04656795</nct_id>
  </id_info>
  <brief_title>PK Study in Subjects With Renal Impairment (Severe and if Required Mild &amp; Moderate) Compared to Subjects With Normal Renal Function</brief_title>
  <official_title>A Single Dose, Non-Randomized, Open-Label, Parallel Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of MT-7117 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Development America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Development America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non randomised, single-dose, study in male and female subjects with&#xD;
      renal impairment (severe and if required mild &amp; moderate) compared to male and female&#xD;
      subjects with normal renal function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open Label</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of MT-7117</measure>
    <time_frame>Day 1 to 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from time zero to the last quantifiable concentration (AUC0-last) of MT-7117</measure>
    <time_frame>Day 1 to 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from time zero to infinity (AUC0-∞) of MT-7117</measure>
    <time_frame>Day 1 to 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by incidence of Treatment emergent adverse events</measure>
    <time_frame>Day -1 to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (tmax) of MT-7117</measure>
    <time_frame>Day 1 to 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent elimination half-time of MT-7117 in plasma (t1/2)</measure>
    <time_frame>Day 1 to 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent oral clearance (CL/F) of MT-7117in plasma</measure>
    <time_frame>Day 1 to 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase (Vz/F) of MT-7117in plasma</measure>
    <time_frame>Day 1 to 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound fraction (fu) of MT-7117 in plasma</measure>
    <time_frame>Day 1 to 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed unbound plasma concentration (Cmax,u) of MT-7117 of MT-7117</measure>
    <time_frame>Day 1 to 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the unbound plasma concentration time curve from time zero to the last quantifiable concentration (AUC0-last, u) of MT-7117</measure>
    <time_frame>Day 1 to 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the unbound plasma concentration time curve from time zero to infinity (AUC0-∞, u)of MT-7117</measure>
    <time_frame>Day 1 to 4</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Renal Impairment</condition>
  <condition>Normal Renal Function</condition>
  <arm_group>
    <arm_group_label>Subjects with severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with moderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-7117</intervention_name>
    <description>MT-7117</description>
    <arm_group_label>Subjects with mild renal impairment</arm_group_label>
    <arm_group_label>Subjects with moderate renal impairment</arm_group_label>
    <arm_group_label>Subjects with normal renal function</arm_group_label>
    <arm_group_label>Subjects with severe renal impairment</arm_group_label>
    <other_name>dersimelagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A subject will be eligible for enrolment in the study if ALL of the following criteria&#xD;
             apply:&#xD;
&#xD;
        For Groups 1, 2, 3 and 4&#xD;
&#xD;
          1. Subject is able to provide written informed consent to participate in this study after&#xD;
             reading the participant information sheet and Informed Consent Form (ICF) and after&#xD;
             having the opportunity to discuss the study with the Investigator or designee.&#xD;
&#xD;
          2. Male or female subjects, ≥ 18 to 80 years of age (inclusive), at the time of signing&#xD;
             the ICF.&#xD;
&#xD;
          3. In the Investigator's opinion, subject is able to understand the nature of the study&#xD;
             and all risks involved with participation in the study and willing to cooperate and&#xD;
             comply with all Protocol restrictions and requirements.&#xD;
&#xD;
          4. Subjects must weigh at least 50 kg (110 pounds) and have a body mass index 18 to 35&#xD;
             kg/m2 both inclusive at Screening and on Day -1.&#xD;
&#xD;
          5. The subject's vital signs must be within the reference range for their age at&#xD;
             Screening and on Day 1. Subjects must have rested for at least 5 minutes in a supine&#xD;
             position prior to collecting blood pressure and pulse. In subjects with normal renal&#xD;
             function, normal blood pressure is considered in the range of 90 to 145 mmHg for&#xD;
             systolic blood pressure (SBP) and 50 to 95 mmHg for diastolic blood pressure (DBP). In&#xD;
             subjects with renal impairment, normal blood pressure is considered in the range of 90&#xD;
             to 179 mmHg for SBP and 50 to 105 mmHg for DBP. Pulse rate should be between 50 to 100&#xD;
             beats per minutes.&#xD;
&#xD;
          6. Female subjects must not be lactating and must have a negative serum pregnancy test at&#xD;
             Screening and on Day 1.&#xD;
&#xD;
          7. Female subjects of child bearing potential and male subjects with a partner of child&#xD;
             bearing potential must agree to use 2 effective methods of contraception (in female&#xD;
             subjects, one method must be highly effective.&#xD;
&#xD;
        For Group 1 (Subjects with Normal Renal Function)&#xD;
&#xD;
          1. Subjects must have an absolute eGFR of ≥ 90 mL/min, as determined by the MDRD&#xD;
             equation, multiplied by the individual BSA according to the DuBois &amp; DuBois equation&#xD;
             and divided by 1.73 m2 at Screening and confirmed at Day 1 (admission to the study&#xD;
             centre).&#xD;
&#xD;
          2. Subjects must be in good health and free from clinically significant illness or&#xD;
             disease in the opinion of the Investigator based upon the results of medical history,&#xD;
             physical examination, clinical laboratory tests (biochemistry, haematology,&#xD;
             coagulation and urinalysis), vital signs and a 12 lead electrocardiogram (ECG) at&#xD;
             Screening and Day -1.&#xD;
&#xD;
          3. Subjects with normal renal function (Group 1) will be matched in pairs by race, age (±&#xD;
             10 years of subject in Group 4), weight (± 10 kg of the subject in Group 4), gender&#xD;
             and smoking status to subjects with severe renal impairment (Group 4).&#xD;
&#xD;
        For Groups 2 to 4 (Subjects with Renal Impairment)&#xD;
&#xD;
          1. Subjects must have stable renal impairment based on medical history, physical&#xD;
             examination and clinical laboratory results. Stable renal impairment is defined as no&#xD;
             clinically significant change in an eGFR within 3 months or longer prior to study&#xD;
             Screening, as determined by the Investigator.&#xD;
&#xD;
          2. Subjects with renal impairment must have the following absolute eGFR values as&#xD;
             determined by the MDRD equation, multiplied by the individual BSA according to the&#xD;
             DuBois &amp; DuBois equation and divided by 1.73 m2 at Screening and confirmed at Day 1&#xD;
             (admission to the study centre) Group 2: Mild renal impairment must have an absolute&#xD;
             eGFR of ≥ 60 to &lt; 90 mL/min Group 3: Moderate renal impairment must have an absolute&#xD;
             eGFR of ≥ 30 to &lt; 60 mL/min Group 4: Severe renal impairment must have an absolute&#xD;
             eGFR of &lt; 30 mL/min; not on dialysis&#xD;
&#xD;
          3. Subjects must have acceptable clinical conditions in the opinion of the Investigator&#xD;
             based upon the results of medical history, physical examination, clinical laboratory&#xD;
             tests (biochemistry, haematology, coagulation and urinalysis), vital signs and a 12&#xD;
             lead ECG at Screening and Day -1.&#xD;
&#xD;
          4. The age of subjects in Groups 2 and 3 must not be more than 10 years younger than the&#xD;
             youngest subject in Group 1 or more than 10 years older than the oldest subject in&#xD;
             Group 1. The weight of subjects in Groups 2 and 3 must not be more than 20% lighter&#xD;
             than the lightest subject in Group 1 or more than 20% heavier than the heaviest&#xD;
             subject in Group 1.&#xD;
&#xD;
          5. Subjects with mild renal impairment (Group 2) and moderate renal impairment (Group 3)&#xD;
             will be matched by race, age, weight and gender to subjects in Group 1 (age and weight&#xD;
             are to be matched as per inclusion criterion 4 above. It is not necessary to match&#xD;
             subjects between Groups 2 and 3 and Group 1 in pairs, but there must be the same&#xD;
             number of each gender and each race in each of Groups 2 and 3 as there are in Group&#xD;
             1).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject will NOT be eligible for this study if ANY of the following criteria apply:&#xD;
&#xD;
        For Groups 1, 2, 3 and 4&#xD;
&#xD;
          1. Subjects who have a known clinically significant hypersensitivity to MT-7117 or&#xD;
             related compounds (or relevant excipients). Subjects who have a history of clinically&#xD;
             significant hypersensitivity, intolerance, allergy or anaphylaxis to any drug&#xD;
             compound, food or other substance unless approved by the Investigator and the Sponsor.&#xD;
&#xD;
          2. Subjects who are currently on dialysis.&#xD;
&#xD;
          3. Subjects who have any active malignancy (including melanoma but excluding basal cell&#xD;
             carcinoma) or history of significant malignancy (including melanoma).&#xD;
&#xD;
          4. Subjects who have previously participated in a study involving MT-7117 within 6 months&#xD;
             prior to the first dose of Investigational Medicinal Product (IMP) and/or subjects who&#xD;
             have previously taken any other investigational drug within 2 months or 5 half-lives&#xD;
             prior to the first dose of IMP, whichever is longer.&#xD;
&#xD;
          5. A history or presence of clinically significant neurological, haematological,&#xD;
             psychiatric, gastrointestinal (including cholecystectomy), pulmonary or hepatic&#xD;
             disease or other condition (with the exception of renal insufficiency for Groups 2 to&#xD;
             4) known to interfere with the absorption, distribution, metabolism or excretion of&#xD;
             drugs or any condition which could place the subjects at increased risk as determined&#xD;
             by the Investigator.&#xD;
&#xD;
          6. Clinically significant 12-lead ECG abnormalities, including subjects with corrected QT&#xD;
             interval using Fridericia's formula (QTcF) of &gt; 450 ms (male) and &gt; 470 ms (female),&#xD;
             at Screening or Day -1, confirmed by repeat assessment.&#xD;
&#xD;
          7. Subject takes non-permitted concomitant medication within 28 days (or 5 half lives of&#xD;
             the drug, whichever is longer) of dosing on Day 1. Subjects with normal renal function&#xD;
             are restricted from use of any concomitant medications unless discussed and agreed&#xD;
             with the Sponsor. For renal impaired subjects, prescribed medication or over the&#xD;
             counter (OTC) medication for treating underlying disease states or chronic medical&#xD;
             conditions or disorders related to renal impairment are permitted as described in the&#xD;
             protocol. If subjects with renal impairment are on any medication not listed in the&#xD;
             protocol, this must be discussed with the Sponsor on a case-by-case basis, prior to&#xD;
             the subject's inclusion in the study.&#xD;
&#xD;
          8. Subjects who have a positive drug screen at Screening or Day 1 (admission to the study&#xD;
             centre), unless the positive drug screen is due to prescription drug use that is&#xD;
             approved by the Investigator and the Sponsor.&#xD;
&#xD;
          9. Subjects who have a positive human immunodeficiency virus (HIV) antibody at Screening.&#xD;
             Consent and counselling for this procedure will be performed according to the site's&#xD;
             Standard Operating Procedures.&#xD;
&#xD;
         10. Subjects who have a positive test for hepatitis B surface antigen (HBsAg), hepatitis B&#xD;
             core antibody (HBcAb) or hepatitis C antibody (HCVAb) at Screening.&#xD;
&#xD;
         11. Acute illness or infection, minor surgical procedures or trauma from within 2 weeks&#xD;
             before Screening until administration of study drug.&#xD;
&#xD;
         12. Subjects who have a history of kidney, other organ or bone marrow transplant.&#xD;
&#xD;
         13. Subjects who have a history of major surgery within 3 months before Day 1.&#xD;
&#xD;
         14. Subjects who have a history of long QT syndrome or cardiac brady-tachy-arrhythmia.&#xD;
&#xD;
         15. Donation of 1 or more units of blood (≥ 450 mL) in the 3 months prior to Screening or&#xD;
             plasma in the 7 days prior to Screening or platelets in the 6 weeks prior to Screening&#xD;
             or intention to donate blood within 3 months after the final follow-up assessment.&#xD;
&#xD;
         16. Subjects who have consumed liquorice, grapefruit or grapefruit juice, orange or their&#xD;
             associated products, within 7 days prior to study treatment on Day 1.&#xD;
&#xD;
         17. Subjects who are smokers or use tobacco or nicotine containing products (snuff,&#xD;
             chewing tobacco, cigarettes, cigars, pipes, e-cigarettes or nicotine replacement&#xD;
             products) and currently smoke more than 10 cigarettes or equivalent per day or are&#xD;
             unable or unwilling to stop from 4 hours pre-dose until 6 hours post dose.&#xD;
&#xD;
         18. Subjects who are not willing to abstain from consumption of caffeine and&#xD;
             methylxanthine (e.g., coffee, tea, cola, energy drinks or chocolates) in the 36 hours&#xD;
             before Day 1 until completion of the post-treatment assessments on Day 4 and in the 36&#xD;
             hours before the Follow-up/EoS Visit on Day 8.&#xD;
&#xD;
         19. Subjects who regularly, or on average, drink more than 21 units (168 g) for males or&#xD;
             14 units (112 g) for females, of alcohol per week (1 unit is equivalent to 8g of&#xD;
             alcohol).&#xD;
&#xD;
         20. Subjects with any other condition or reason that, in the opinion of the Investigator&#xD;
             or Sponsor, would make the subject unsuitable for enrolment.&#xD;
&#xD;
         21. Subjects who test positive for Coronavirus Disease 2019 at Screening or Day -1.&#xD;
&#xD;
         22. Subject with the presence of a skin lesion suspicious for dysplastic naevus or a&#xD;
             history of histologically proven dysplastic naevus.&#xD;
&#xD;
        Group 1 (Subjects with Normal Renal Function):&#xD;
&#xD;
        (1) Subjects with aspartate aminotransferase (AST), alanine aminotransferase (ALT),&#xD;
        gamma-glutamyl transpeptidase (GGT) or total bilirubin level (TBL) &gt; 1.5 times upper limit&#xD;
        of normal (ULN) during Screening or at Day 1.&#xD;
&#xD;
        For Groups 2, 3 and 4 (Subjects with Renal Impairment)&#xD;
&#xD;
          1. Use of concurrent medications, which affect the eGFR such as cephalosporin&#xD;
             antibiotics, ascorbic acid, trimethoprim, cimetidine or quinine for at least 28 days&#xD;
             prior to Day 1 (or 5 half-lives of the drug, whichever is longer).&#xD;
&#xD;
          2. Subject who has renal disease secondary to malignancy.&#xD;
&#xD;
          3. Subjects with acute renal failure.&#xD;
&#xD;
          4. Subject with any of the liver function test (AST, ALT, ALP and TBL) out of the&#xD;
             following range (TBL &gt; 1.5 × ULN, ALT and AST &gt; 2 × ULN and ALP &gt; 3 × ULN) at&#xD;
             Screening or Day -1.&#xD;
&#xD;
          5. Subjects have serum albumin &lt; 30 g/L and haemoglobin &lt; 8 g/dL&#xD;
&#xD;
          6. Subject has not been on a stable dose of concomitant medications for the previous 28&#xD;
             days and/or has started new medications to treat concurrent chronic conditions in the&#xD;
             previous 28 days (or 5 half lives of the drug, whichever is longer) prior to IMP&#xD;
             dosing. Minor dose adjustments to the subject's regular medication may be allowed up&#xD;
             to 14 days prior to IMP dosing after consultation with the Sponsor. This medication&#xD;
             regimen should not change whilst the subject is enrolled in the study.&#xD;
&#xD;
          7. Any clinically significant abnormalities, other than those associated with the&#xD;
             subject's degree of renal impairment, in biochemistry, haematology, coagulation and&#xD;
             urinalysis results as judged by the Investigator and the Sponsor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of Medical Science</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Development America, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mitsubishi Tanabe Pharma Europe Ltd General Information To prevent mis-communication,</last_name>
    <phone>please e-mail</phone>
    <email>regulatory@mt-pharma-eu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Services (CRS) Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PK Study in subjects with renal impairment (severe and if required mild &amp; moderate) vs. subjects with normal renal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

